Tilray Inc (NASDAQ:TLRY – Get Free Report) has received a consensus rating of “Hold” from the four analysts that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $2.71.
TLRY has been the topic of a number of recent analyst reports. CIBC decreased their target price on Tilray from $2.25 to $2.00 and set a “neutral” rating on the stock in a report on Wednesday, April 10th. Alliance Global Partners boosted their target price on Tilray from $2.25 to $2.75 and gave the stock a “neutral” rating in a report on Friday, April 5th. Finally, Canaccord Genuity Group reduced their price target on Tilray from $4.25 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, April 10th.
Read Our Latest Stock Report on Tilray
Institutional Trading of Tilray
Tilray Stock Up 2.8 %
TLRY stock opened at $1.83 on Wednesday. The company has a current ratio of 1.92, a quick ratio of 1.18 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $1.36 billion, a PE ratio of -4.16 and a beta of 2.36. Tilray has a 1-year low of $1.50 and a 1-year high of $3.40. The business’s 50 day simple moving average is $1.97 and its 200 day simple moving average is $1.97.
About Tilray
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Stories
- Five stocks we like better than Tilray
- What is a buyback in stocks? A comprehensive guide for investors
- Silicon Motion Proves That AI in Motion Stays in Motion
- What is a Secondary Public Offering? What Investors Need to Know
- Undervalued UnitedHealth Group Won’t Be For Long
- 3 Ways To Invest In Coffee, Other Than Drinking It
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.